Biotechnology company GeoVax Labs will provide insights into its cutting-edge medical research during the upcoming 37th Annual Roth Conference, where CEO David Dodd will participate in a fireside chat discussing the company's promising clinical developments in vaccine and cancer therapy technologies.
The presentation, scheduled for March 17, 2025, will focus on GeoVax's lead clinical programs, including GEO-CM04S1, a next-generation COVID-19 vaccine designed to address limitations in current vaccination strategies. The vaccine is currently undergoing multiple Phase 2 clinical trials targeting specific patient populations, including immunocompromised individuals and patients with chronic lymphocytic leukemia.
A significant milestone for the company is a recently awarded BARDA-funded contract to conduct a 10,000-participant Phase 2b clinical trial comparing GEO-CM04S1 against existing approved COVID-19 vaccines. This extensive study represents a critical step in potentially expanding vaccination options for vulnerable patient groups who have not achieved optimal immune responses with current vaccines.
Beyond infectious disease research, GeoVax is also advancing oncological treatments. The company is evaluating Gedeptin®, an innovative oncolytic solid tumor gene-directed therapy. Having completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, the company plans a Phase 2 clinical trial combining Gedeptin® with an immune checkpoint inhibitor for first recurrent head and neck cancer patients.
The Roth Conference presentation provides an opportunity for investors and industry professionals to gain comprehensive insights into GeoVax's research pipeline and potential breakthrough medical technologies. By simultaneously addressing challenges in both infectious disease prevention and cancer treatment, the company demonstrates a multifaceted approach to addressing critical global health challenges.
With a leadership team experienced in driving value across life science sectors and a robust intellectual property portfolio, GeoVax continues to position itself at the forefront of innovative medical research, potentially offering new therapeutic strategies for complex medical conditions.
